Capital Fund Management S.A. lowered its position in shares of Intrexon Corp. (NYSE:XON) by 56.8% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 64,927 shares of the company’s stock after selling 85,493 shares during the period. Capital Fund Management S.A.’s holdings in Intrexon Corp. were worth $1,598,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in XON. Sanders Morris Harris Inc. boosted its stake in Intrexon Corp. by 93.6% in the second quarter. Sanders Morris Harris Inc. now owns 85,000 shares of the company’s stock worth $2,092,000 after buying an additional 41,100 shares in the last quarter. Cacti Asset Management LLC bought a new stake in Intrexon Corp. during the second quarter worth approximately $246,000. Legal & General Group Plc boosted its stake in Intrexon Corp. by 3.4% in the first quarter. Legal & General Group Plc now owns 3,788 shares of the company’s stock worth $128,000 after buying an additional 126 shares in the last quarter. Cupps Capital Management LLC bought a new stake in Intrexon Corp. during the first quarter worth approximately $1,368,000. Finally, Alpine Partners VI LLC bought a new stake in Intrexon Corp. during the first quarter worth approximately $292,000. Hedge funds and other institutional investors own 84.05% of the company’s stock.
Intrexon Corp. (NYSE:XON) traded up 4.07% during trading on Friday, hitting $29.69. The stock had a trading volume of 1,387,993 shares. Intrexon Corp. has a 12-month low of $18.52 and a 12-month high of $43.76. The company has a 50 day moving average of $27.34 and a 200-day moving average of $28.08. The company’s market cap is $3.51 billion.
Intrexon Corp. (NYSE:XON) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.16. The firm earned $52.50 million during the quarter, compared to analyst estimates of $53.78 million. Intrexon Corp. had a negative net margin of 96.65% and a negative return on equity of 19.00%. The company’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.37) EPS. On average, equities analysts predict that Intrexon Corp. will post ($1.36) EPS for the current year.
A number of analysts recently commented on XON shares. Stifel Nicolaus reiterated a “buy” rating and set a $57.00 price objective on shares of Intrexon Corp. in a research report on Wednesday, June 29th. Wunderlich reiterated a “buy” rating and set a $50.00 price objective on shares of Intrexon Corp. in a research report on Thursday, July 7th. JMP Securities reiterated a “buy” rating on shares of Intrexon Corp. in a research report on Sunday, July 17th. Zacks Investment Research upgraded Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Tuesday, July 19th. Finally, Vetr cut Intrexon Corp. from a “strong-buy” rating to a “sell” rating and set a $22.26 price objective for the company. in a research report on Wednesday, July 20th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Intrexon Corp. has a consensus rating of “Buy” and a consensus target price of $41.71.
In related news, SVP Nir Nimrodi bought 4,000 shares of the business’s stock in a transaction dated Monday, August 29th. The shares were bought at an average cost of $26.12 per share, with a total value of $104,480.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 55.10% of the stock is owned by insiders.
Intrexon Corp. Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.